Vineti, Inc., a San Francisco, CA-based digital platform of record for personalized therapeutics, closed a $35m Series C funding round.
The round was led by Cardinal Health, with participation from Novartis Pharma AG and Kite, a Gilead Company (Gilead Sciences, Inc.), as well as existing investors Canaan Partners, Threshold Ventures (formerly DFJ), Section 32, LifeForce Capital, Casdin Capital, and Hive Ventures, along with other undisclosed entities. A representative of Cardinal Health will join Vineti’s Board of Directors, and representatives of Novartis and Kite will join as board observers.
The company intends to use the funds for enhance its automation and analytics offering, develop new software product, and expand globally.
Led by Amy DuRoss, CEO and Co-Founder, Vineti provides a cloud-based platform of record to integrate logistics, manufacturing and clinical data for personalized therapies. The software solution aligns and orchestrates the cell and gene therapy process and improves product performance overall. The platform supports the full continuum of patient-specific therapies, including cancer vaccines and autologous and allogeneic therapies. It can also be harnessed for drug products requiring companion diagnostics or REMS programs. Vineti is currently serving patients, healthcare providers, and researchers in hundreds of leading medical centers and manufacturing centers world-wide, on behalf of a growing number of biopharmaceutical partners.
Vineti is headquartered in San Francisco, California, with offices in Bethesda, Maryland and Yerevan, Armenia.